Investor Overview

Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.



Copyright West LLC. Minimum 15 minutes delayed.

Recent News

Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting


Tocagen Reports Third Quarter 2019 Financial Results and Business Updates


Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting

Recent Presentation
Upcoming Events
There are currently no events scheduled.